{"name":"Zai Lab (Shanghai) Co., Ltd.","slug":"zai-lab-shanghai-co-ltd","ticker":"","exchange":"","domain":"zailabshanghai.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"oncology","drugs":[{"name":"ZL-1109 (VRDN-003)","genericName":"ZL-1109 (VRDN-003)","slug":"zl-1109-vrdn-003","indication":"Non-small cell lung cancer, PD-L1 positive","status":"phase_3"},{"name":"Brivanib 400 mg, BID","genericName":"Brivanib 400 mg, BID","slug":"brivanib-400-mg-bid","indication":"Hepatocellular carcinoma (Phase 2)","status":"phase_2"},{"name":"Brivanib 800 mg, QD","genericName":"Brivanib 800 mg, QD","slug":"brivanib-800-mg-qd","indication":"Hepatocellular carcinoma","status":"phase_2"},{"name":"ZL-1310","genericName":"ZL-1310","slug":"zl-1310","indication":"FGFR-positive or FGFR-altered solid tumors","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"immunology","drugs":[{"name":"ZL-1201","genericName":"ZL-1201","slug":"zl-1201","indication":"Other","status":"phase_1"},{"name":"Investigator's Choice of Therapy","genericName":"Investigator's Choice of Therapy","slug":"investigator-s-choice-of-therapy","indication":"Other","status":"phase_3"},{"name":"ZL-1503","genericName":"ZL-1503","slug":"zl-1503","indication":"Other","status":"phase_1"},{"name":"ZL-6201","genericName":"ZL-6201","slug":"zl-6201","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"ZL-1109 (VRDN-003)","genericName":"ZL-1109 (VRDN-003)","slug":"zl-1109-vrdn-003","phase":"phase_3","mechanism":"ZL-1109 (VRDN-003) is a small molecule targeting the PD-1 receptor.","indications":["Non-small cell lung cancer, PD-L1 positive"],"catalyst":""},{"name":"ZL-1201","genericName":"ZL-1201","slug":"zl-1201","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Brivanib 400 mg, BID","genericName":"Brivanib 400 mg, BID","slug":"brivanib-400-mg-bid","phase":"phase_2","mechanism":"Brivanib is a dual inhibitor of fibroblast growth factor receptor (FGFR) and vascular endothelial growth factor receptor (VEGFR) that blocks angiogenesis and tumor cell proliferation.","indications":["Hepatocellular carcinoma (Phase 2)","Advanced solid tumors (Phase 2)"],"catalyst":""},{"name":"Brivanib 800 mg, QD","genericName":"Brivanib 800 mg, QD","slug":"brivanib-800-mg-qd","phase":"phase_2","mechanism":"Brivanib is a dual inhibitor of fibroblast growth factor receptor (FGFR) and vascular endothelial growth factor receptor (VEGFR) that blocks angiogenesis and tumor cell proliferation.","indications":["Hepatocellular carcinoma","Advanced solid tumors"],"catalyst":""},{"name":"Investigator's Choice of Therapy","genericName":"Investigator's Choice of Therapy","slug":"investigator-s-choice-of-therapy","phase":"phase_3","mechanism":"Investigator's Choice of Therapy is a flexible treatment approach where the treating physician selects from approved or standard-of-care therapeutic options based on individual patient characteristics.","indications":[],"catalyst":""},{"name":"ZL-1310","genericName":"ZL-1310","slug":"zl-1310","phase":"phase_3","mechanism":"ZL-1310 is a selective inhibitor of fibroblast growth factor receptor (FGFR) that blocks aberrant FGFR signaling in cancer cells.","indications":["FGFR-positive or FGFR-altered solid tumors","Cholangiocarcinoma with FGFR alterations"],"catalyst":""},{"name":"ZL-1503","genericName":"ZL-1503","slug":"zl-1503","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ZL-6201","genericName":"ZL-6201","slug":"zl-6201","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxPUnpOeXhoczBENjI3NUw0bFhQU2l2Um1lMXVPNUZkMmNSelFoUHUyQWR1NVE3N0tobU1xWHJxQUNWWU13MVNiS1MxVmwtSDlVWVYyTmwxLXc2NlJvLW85UGtsQndPQi1sQ0lsVDJPdXlmYVZxd2RCN29mcjY3bW1OR0VmQllTeFZ1QWFRQzFJUlhHWEhIaWhCSw?oc=5","date":"2026-03-10","type":"trial","source":"openPR.com","summary":"Advanced Hepatocellular Carcinoma Clinical Trial Pipeline - openPR.com","headline":"Advanced Hepatocellular Carcinoma Clinical Trial Pipeline","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6wFBVV95cUxPRV9sYWFLSkV3VkRaR2p1VWtRMmtOMUhnYUttV2F4Ym1lQjJHV2pBeERSYWEzNUNKRFh0dlZsRHUxZ1RmdFFlUEtyOTA2bDhpVHFtckQ1QnYxZHN4QVQ1US1jTFR6VnhVenktZnFnSjlrLWxGbFFtNllCajlfd3ZaTU52OHFZQ19LU3ZyQzlKV2ItSnJZeGdCOUp6dEFRbHlDQUhFeFVGUldHQ0RWUjZKMGlxYmdIeWlqeWYwTW12QnpWSlc4M3lRTmc1WlZGWUtqamo0Y1d5OHc2ZDhLcW82RDI3VDFNTE5GbkUw?oc=5","date":"2026-02-26","type":"earnings","source":"businesswire.com","summary":"Zai Lab Announces Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates - businesswire.com","headline":"Zai Lab Announces Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7AFBVV95cUxNZGNDUDdJdlJ0WXRfSWlVd2dsMnM2ZmxSZ1hSU2JGeUJpaTdpRUhiRU5HWXhoZU1jZFh2YWtndWdxWWFPWURGYTRkVHNkNF9VZ1hlMVdhTFhucUxOQmNyTnE3UThLMnRUWE9Nby15VEI5eTNTNjk0c0xSYlRDVXZqanlnRVgyNzR3NUhYXzE4S0xvd3dmOTJvblFkVzhSNzYzR2pCZ1pYQlNINXR0TjBCSE5pX3pnNE5SWGt1a0xYOHZjODFBc0RsdVZLVHVJc0xGNW5hX1VBdmMwUnRzZ2g0MHdZYkM2NnNQRURYRg?oc=5","date":"2026-01-13","type":"pipeline","source":"BioSpace","summary":"Zai Lab Highlights Strategic Priorities and Global Pipeline Progress at 44th Annual J.P. Morgan Healthcare Conference - BioSpace","headline":"Zai Lab Highlights Strategic Priorities and Global Pipeline Progress at 44th Annual J.P. Morgan Healthcare Conference","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_wFBVV95cUxPTW5WNnF3QkRTRFQ0cDRJSEpKQnE4ZUJQTVdtRW42enlJLUFvdjVDVHVQM25SdDQtc1ZkbFlOWmFUS0tISFpZRTZOMmx6VTJ6Y3pReUctZmozSTEtZFFyMmZrY2ZZSy02TVNJcm9XWlpOZVg3cWpCbjRDQUxjektjeXpIU3lHQnZkSjhqMVpYOXBDQ2pkTEZOQWFJVGtmN0szU3ViUTl2eEM5M2tJcm1zZXk3LWlKOWxnZy1rZXV4X1A5WlJCZ0tKNGx1dVpKRDJQZ2l2dldqX29veDN6cEduMlNhU3NWdmxNeTRBNkEzSXVENXVlSEFqY3lITzJERzQ?oc=5","date":"2025-09-12","type":"deal","source":"Citeline News & Insights","summary":"The Rise In China Deals: How International Biopharma Is Turning To China For Innovation - Citeline News & Insights","headline":"The Rise In China Deals: How International Biopharma Is Turning To China For Innovation - Citeline News & Insights","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxOUmdRMlBDOUotZzdPTllINWgwdGg0UWJCRE44YVlnRDNFRVBjWklzMEhEUmZuemZWcmQ1WmU3RkEwbFcxZzNOSVhoUlJKaFBYbzJaaDMyby1fRU10bGpGcUdzVTdvNmw0STI0YVI5OWNUaTlQbkRwZmJFZ3cwSEdrSU5VR1lzZm85NTdBcEpRTlpQT3ZBN0dMZ0tPd2c?oc=5","date":"2025-09-09","type":"trial","source":"BioWorld News","summary":"How lung the wait for another DLL3? Data showing promise - BioWorld News","headline":"How lung the wait for another DLL3? Data showing promise","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-07-25","type":"pipeline","source":"simplywall.st","summary":"Zai Lab Limited's (NASDAQ:ZLAB) large institutional owners must be happy as stock continues to impress, up 4.9% over the past week - simplywall.st","headline":"Zai Lab Limited's (NASDAQ:ZLAB) large institutional owners must be happy as stock continues to impress, up 4.9% over the","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxQcmNCZGNiaVQyeF8zeWVmQ2M5N1ZEcFFNQkxuS0lKX09vcDVVZzAtak5xak9Sb1B6ZzN5NE01dGM0aXIwQWJwOTV4WHM3dGJzZkZiTWRNa19GdElMZEFPTlhNZW5OenhfcTBWZjZLVGNhMEZ2cnItSDN5a1Fwelh6RUJzcnYtdVpmU2JIbjNqUXlZRWdaT2ttdjUyLW0?oc=5","date":"2024-11-15","type":"pipeline","source":"The Pharma Letter","summary":"Zai Lab prices public offering to raise $200 million - The Pharma Letter","headline":"Zai Lab prices public offering to raise $200 million","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMickFVX3lxTFBFcDNtMUpUSnN6Q1hzcjJsTUJmMFJoTjRLdHFSdG5ldjRHQmpvaDZ2SzRVUnRmZGRSajZ6VXJJYXRJQTI1VUJJdmtUQkxXaTRDZXNQZnd1STdPQlVkLWVOc1RRZ3pIX2VBZTR2TlpyY2ZIQQ?oc=5","date":"2023-06-12","type":"pipeline","source":"Pharma Voice","summary":"Zai Lab looks to expand beyond China and make a global impact in oncology - Pharma Voice","headline":"Zai Lab looks to expand beyond China and make a global impact in oncology","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2023-05-31","type":"trial","source":"GlobeNewswire","summary":"B-Cell Lymphoma Clinical Trial Pipeline Insights: - GlobeNewswire","headline":"B-Cell Lymphoma Clinical Trial Pipeline Insights:","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxQcjZPOFdlMnRYZXgxXzJyY1pHOVgzSmF1OGNweUdUNVE4VmJwUUo2NU5TSjlKLTRRb1o5eGdScHo5RHF4VDVvYnhOU3VOTU94S2pIOXJvOXd3RTktRDFuM3BmQnRUOVhvZGdJcmhWRkNDRVNPN1IwcF9wSDc4ci1JeUJ4RkNUdGJfanNFUGM1LS1SYy1GWXRVYmZwenpHVWQ1?oc=5","date":"2022-09-28","type":"pipeline","source":"The Business Journals","summary":"A Chinese pharma plans fast expansion of Cambridge HQ - The Business Journals","headline":"A Chinese pharma plans fast expansion of Cambridge HQ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMieEFVX3lxTE1Mb0REVGt6WWJCTlRfRG5PNTZrSUZJVTZIU1NWOXdkSzNkend0elpjcVdkUGo1UmdLQTMyM2RzZ2dXOUUyRDNlUkNDZklWa1hlWXVWZmNLSUlva2xvdTFzckVNMmRmbllPOVJ1TlNaQWVmSW9zNlJNZQ?oc=5","date":"2020-11-10","type":"pipeline","source":"Fierce Pharma","summary":"10 biotechs to know in China - Fierce Pharma","headline":"10 biotechs to know in China","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxQX2szRi1md29fNzNpSFRIMWU3VzdoMFllRXdUdzVtUEpoNUdILTN0d0c0d3hpX3o1dlpaRDJjNnhfdHlncHlNTHkwQ20xYm1LUTNudEQteUY2NXp0VS00THNXQWJlaXpOOXhnVU41T1VwcUJrZGs1S3pRY1V6NWdXVXFlWWYtUkhUdDVQTGJDMmhzTkN6cDNkT05uOGRRSTRlcWhGTF9fVURENVkwYkVB?oc=5","date":"2017-09-27","type":"earnings","source":"Bloomberg.com","summary":"China's Revenue-Free Drug Trip - Bloomberg.com","headline":"China's Revenue-Free Drug Trip","sentiment":"neutral"}],"patents":[],"drugCount":8,"phaseCounts":{"phase_3":3,"phase_1":3,"phase_2":2},"enrichmentLevel":2,"visitCount":4,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}